Shots:
- As 2025 wrapped up, the final quarter made one thing clear: biopharma is doubling down on scale, science, and speed. From October to December, the industry saw a surge in high-value M&A and strategic collaborations, with companies racing to strengthen pipelines across neuroscience, oncology, metabolic diseases, and next-generation platforms
- The quarter was led by headline-grabbing acquisitions such as Novartis’ ~$12B buyout of Avidity Biosciences and Merck’s ~$9.2B acquisition of Cidara Therapeutics, underscoring continued confidence in late-stage and differentiated assets
- Partnerships also took center stage, highlighted by Pfizer’s ~$2.1B licensing deal with YaoPharma for a next-generation GLP-1 therapy aimed at chronic weight management. Below is a snapshot of the deals and collaborations that shaped Q4’25
October: Kicking Off with Strategic Scale
- Halozyme Therapeutics strengthened its drug delivery capabilities by acquiring Elektrofi for ~$900M, gaining access to Hypercon technology that enables ultra-high concentration biologics.
- Novo Nordisk expanded its MASH ambitions with a ~$5.2B acquisition of Akero Therapeutics, bringing in late-stage asset efruxifermin (EFX).
- Bristol Myers Squibb reinforced its cell therapy strategy through a $1.5B acquisition of Orbital Therapeutics, adding an AI-driven RNA platform and circular RNA assets.
- BioCryst Pharmaceuticals entered a ~$700M cash-and-stock deal to acquire Astria Therapeutics, bolstering its rare disease and immunology pipeline.
- Boston Scientific continued its push in neuromodulation with the ~$533M acquisition of Nalu Medical, enhancing its chronic pain portfolio.
- Ipsen deepened its oncology footprint by acquiring ImCheck Therapeutics, with total deal value potentially reaching €1B, anchored by γδ T-cell–activating antibody ICT01.
- Alkermes made a decisive entry into sleep medicine with a ~$2.1B acquisition of Avadel Pharmaceuticals, centered on narcolepsy therapy Lumryz.
- Novartis capped the month with its ~$12B acquisition of Avidity Biosciences, significantly boosting its neuroscience pipeline with AOC technology.
- Eli Lilly strengthened its gene therapy capabilities through the acquisition of Adverum Biotechnologies, adding wet AMD candidate Ixo-vec.
- Thermo Fisher Scientific closed October by announcing a ~$9.4B acquisition of Clario, expanding its digital and data-driven clinical research offerings.
November: Innovation Meets Collaboration
- Manifold Bio and Roche entered a landmark partnership worth over $2B to develop next-generation BBB shuttle technologies for neurological diseases.
- Lyell Immunopharma secured global rights to LYL273 in an ~$860M deal, targeting metastatic colorectal cancer.
- Transition Bio and Voyager Therapeutics teamed up in a ~$500M collaboration to develop small molecules for neurodegenerative diseases.
- Day One Biopharmaceuticals acquired Mersana Therapeutics, adding ADC capabilities through a structured CVR-based transaction.
- Adagene and Third Arc Bio signed an ~$845M licensing deal focused on masked CD3 T-cell engagers.
- Merck continued its acquisition streak with a ~$9.2B purchase of Cidara Therapeutics, adding long-acting antiviral CD388.
- Johnson & Johnson accelerated its oncology innovation via a $3.05B acquisition of Halda Therapeutics and its RIPTAC platform.
- Abbott made one of the quarter’s largest moves, acquiring Exact Sciences for ~$23B, cementing its leadership in cancer diagnostics.
- GE HealthCare expanded its AI and imaging capabilities with a $2.3B acquisition of Intelerad.
- Gilead Sciences added a promising oncology program by acquiring Sprint Bioscience’s TREX1 asset.
December: Ending the Year on a High Note
- Akebia Therapeutics picked up complement inhibitor ADX-097 from Q32 Bio in a ~$592M deal.
- Natera strengthened its MRD leadership with a ~$450M acquisition of Foresight Diagnostics, enhancing ultra-sensitive cancer detection.
- Viatris monetized its stake in Biocon Biologics for ~$815M, reshaping its biosimilars strategy.
- Mirum Pharmaceuticals expanded its rare liver disease portfolio by acquiring Bluejay Therapeutics.
- Pfizer deepened its metabolic disease pipeline through a ~$2.1B collaboration with YaoPharma for a GLP-1 agonist.
- Zealand Pharma and OTR Therapeutics announced a ~$2.5B collaboration to develop oral metabolic disease therapies.
- Sobi entered a ~$1.5B acquisition to strengthen its gout pipeline with Arthrosi Therapeutics.
- BioMarin closed a ~$4.8B acquisition of Amicus Therapeutics, expanding its rare disease commercial portfolio.
- Shionogi acquired the Radicava franchise from Tanabe Pharma in a $2.5B rare disease deal.
- Sanofi wrapped up the year with a ~$2.2B acquisition of Dynavax, adding vaccines and immunology assets.
The Big Picture
Q4’25 showcased a biopharma industry that’s confident, competitive, and increasingly focused on platform-driven science, late-stage certainty, and long-term differentiation. As we move into 2026, the momentum from these deals sets the tone for another year of accelerated innovation and strategic consolidation.
